FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry and dermatology and is a pharmaceutical composition comprising 0.003 % by weight of ivermectin relative to the total weight of the composition in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of atopic dermatitis.
EFFECT: invention reduces inflammatory effect and is effective in the treatment and/or prevention of atopic dermatitis with reduced or no side effect.
5 cl, 6 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AVERMECTIN OR MILBEMYCIN FAMILY COMPOUND FOR TREATMENT AND/OR PREVENTION OF ADOPIC DERMATITIS | 2014 |
|
RU2792693C2 |
| COMBINATION OF AVERMECTINE OR MILBEMYCIN WITH ADRENERGIC RECEPTORS FOR TREATING OR PREVENTING DERMATOLOGICAL DISEASES | 2010 |
|
RU2531087C2 |
| TREATMENT OF INFLAMMATORY DAMAGES IN CASE OF ROSAZEA USING IVERMECTIN | 2014 |
|
RU2633481C2 |
| COMPOSITIONS AND USE THEREOF FOR TREATING OR PREVENTING ROSACEA | 2017 |
|
RU2738932C2 |
| PAPULOPUSTULAR ROSACEA TREATMENT BY IVERMECTIN | 2014 |
|
RU2633076C2 |
| CREAM GEL CONTAINING IVERMECTIN | 2005 |
|
RU2389494C2 |
| PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION CONTAINING COMBINATION OF FUSIDIC ACID AND CORTICOSTEROID | 2008 |
|
RU2470645C2 |
| USE OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS | 2017 |
|
RU2752785C2 |
| COMPOSITION FOR ATOPIC ECZEMA PREVENTION OR TREATMENT CONTAINING MONOACETYLDIACYL GLYCERINE COMPOUND AS ACTIVE INGREDIENT | 2014 |
|
RU2640503C2 |
| MEANS FOR THE TREATMENT OF ATOPIC DERMATITIS | 2022 |
|
RU2794841C1 |
